Reviews Open access

Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic review

Authors

Published
8 May 2023
Section
Reviews
DOI
10.4081/reumatismo.2023.1548

Abstract

The COVID-19 pandemic represents a global health problem, which has been mitigated by the opportune introduction of vaccination programs. Although we already know the benefit that vaccines provide, these are not exempt from adverse events which can be mild to deadly, such as idiopathic inflammatory myopathies, in which a temporal association has not been defined. It is for this reason that we carried out a systematic review of all reported cases of vaccination against COVID-19 and myositis. To identify previously reported cases of idiopathic inflammatory myopathies associated with vaccination against SARS-CoV-2 we registered this protocol on the website of PROSPERO with identification number CRD42022355551. Of the 63 publications identified in MEDLINE and 117 in Scopus, 21 studies were included, reporting 31 cases of patients with vaccination-associated myositis. Most of these cases were women (61.3%); mean age was 52.3 years (range 19-76 years) and mean time of symptom onset post-vaccination was 6.8 days. More than half of the cases were associated with Comirnaty, 11 cases (35.5%) were classified as dermatomyositis, and 9 (29%) as amyopathic dermatomyositis. In 6 (19.3%) patients another probable trigger was identified. Case reports of inflammatory myopathies associated with vaccination have heterogeneous presentations without any specific characteristics: as a consequence, it is not possible to ensure a temporal association between vaccination and the development of inflammatory myopathies. Large epidemiological studies are required to determine the existence of a causal association.

Keywords

References

  1. Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021; 4: e2035057. DOI: https://doi.org/10.1001/jamanetworkopen.2020.35057
  2. World Health Organization. Available from: https://covid19.who.int/?mapFilter=vaccinations
  3. Butt AA, Talisa VB, Shaikh OS, Omer SB, Mayr FB. Relative vaccine effectiveness of a SARS-CoV-2 mRNA vaccine booster dose against the Omicron variant. Clin Infect Dis. 2022; 75: 2161-8. DOI: https://doi.org/10.1093/cid/ciac328
  4. Adams K, Rhoads JP, Surie D, Gaglani M, Ginde AA, McNeal T, et al. Vaccine effectiveness of primary series and booster doses against Omicron variant COVID-19-associated hospitalization in the United States. medRxiv. 2022; doi: 10.1101/2022.06.09.22276228. DOI: https://doi.org/10.1101/2022.06.09.22276228
  5. Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, et al. COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US states, January 2021 to April 2022. JAMA Intern Med. 2022; 182: 1071-81. DOI: https://doi.org/10.1001/jamainternmed.2022.4299
  6. Mushtaq HA, Khedr A, Koritala T, Bartlett BN, Jain NK, Khan SA. A review of adverse effects of COVID-19 vaccines. Infez Med. 2022; 30: 1-10. DOI: https://doi.org/10.53854/liim-3001-1
  7. Stübgen JP. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev. 2014; 13: 31-9. DOI: https://doi.org/10.1016/j.autrev.2013.08.005
  8. Fernandez PI, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018; 20: 21. DOI: https://doi.org/10.1007/s11926-018-0732-6
  9. Orbach H, Tanay A. Vaccines as a trigger for myopathies. Lupus. 2009; 18: 1213-6. DOI: https://doi.org/10.1177/0961203309345734
  10. Betteridge Z, Tansley S, Shaddick G, Chinoy H, CooperRG, New RP, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019; 101: 48-55. DOI: https://doi.org/10.1016/j.jaut.2019.04.001
  11. Chaima K, Mariem A, Sana B, Khadija S, Mariem R, Massara B, et al. Vaccine-induced dermatomyositis following COVID-19 vaccination. Dermatol Ther. 2022; 35: e15749. DOI: https://doi.org/10.1111/dth.15749
  12. Venkateswaran K, Aw DCW, Huang J, Angkodjojo S. Dermatomyositis following COVID-19 vaccination. Dermatol Ther. 2022; 35: e15479. DOI: https://doi.org/10.1111/dth.15479
  13. Gouda W, Albasri A, Alsaqabi F, Al Sabah HY, Alkandari M, Abdelnaby H. Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination. J Korean Med Sci. 2022; 37: e32. DOI: https://doi.org/10.3346/jkms.2022.37.e32
  14. Holzer MT, Krusche M, Ruffer N, Haberstock H, Stephan M, Huber TB, et al. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol. 2022; 42: 2267-76. DOI: https://doi.org/10.1007/s00296-022-05176-3
  15. Aimo C, Mariotti EB, Corr A, Quintarelli L, Bianchi B, Verdelli A, et al. Lymphedema of the arm after COVID-19 vaccination in a patient with hidden breast cancer and paraneoplastic dermatomyositis. Vaccines. 2022; 10: 1219. DOI: https://doi.org/10.3390/vaccines10081219
  16. Magen E, Mukherjee S, Bhattacharya M, Detroja R, Merzon E, Blum I, et al. Clinical and molecular characterization of a rare case of BNT162b2 mRNA COVID-19 vaccine-associated myositis. Vaccines. 2022; 10: 1135. DOI: https://doi.org/10.3390/vaccines10071135
  17. Camargo Coronel A, Jiménez Balderas FJ, Quiñones Moya H, Hernández Zavala MR, Mandinabeitia Rodríguez P, Hernández Vázquez JR, et al. Dermatomyositis post vaccine against SARS-COV2. BMC Rheumatol. 2022; 6: 20. DOI: https://doi.org/10.1186/s41927-022-00250-6
  18. Huang ST, Lee TJ, Chen KH, Sun HY, Chen WT, Hsieh SC, et al. Fatal myositis, rhabdomyolysis and compartment syndrome after ChAdOx1 nCoV-19 vaccination. J Microbiol Immunol Infect. 2022; 55: 1131-3. DOI: https://doi.org/10.1016/j.jmii.2022.04.003
  19. Vutipongsatorn K, Isaacs A, Farah Z. Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports. J Med Case Rep. 2022; 16: 57. DOI: https://doi.org/10.1186/s13256-022-03266-1
  20. GonzalezD,GuptaL,MurthyV,GonzalezEB, Williamson KA, Makol A, et al. Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. Rheumatol Int. 2022; 42: 1629-41. DOI: https://doi.org/10.1007/s00296-022-05149-6
  21. Wu M, Karim M, Ashinoff R. COVID-19 vaccine-associated dermatomyositis. JAAD Case Reports. 2022; 23: 58-60. DOI: https://doi.org/10.1016/j.jdcr.2022.02.023
  22. Kim JH, Kim JH, Woo CG. Clinicopathological characteristics of inflammatory myositis induced by COVID-19 vaccine (Pfizer-BioN-Tech BNT162b2): a case report. J Korean Med Sci. 2022; 37: e91. DOI: https://doi.org/10.3346/jkms.2022.37.e91
  23. Kondo Y, Oyama M, Nakamura Y, Matsubara S, Tanikawa A, Kaneko Y. Dermatomyositis-like rash and inflammatory myopathy after mRNA-1273 vaccination. Rheumatol. 2022; 61: e171-3. DOI: https://doi.org/10.1093/rheumatology/keac038
  24. Lee AYS, Lee C, Brown DA, Suan D. Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination. Postgrad Med J. 2022; postgradmedj-2022-141510. DOI: https://doi.org/10.1136/postgradmedj-2022-141510
  25. Kreuter A, Lausch S, Burmann SN, Paschos A, Michalowitz AL. Onset of amyopathic dermatomyositis following mRNA-based SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol. 2022; 36: e669-72. DOI: https://doi.org/10.1111/jdv.18211
  26. Ooi XT, Choi EC, Lee JS. Manifestation of a cancer-associated TIF-1 gamma dermatomyositis after COVID-19 vaccine. Int J Dermatol. 2022; 61: 1425-6. DOI: https://doi.org/10.1111/ijd.16358
  27. Durucan I, Guner S, Kilickiran Avci B, Unverengil G, Melikoglu M, Ugurlu S. Post Covıd-19 vaccınatıon inflammatory syndrome: a case report. Mod Rheumatol Case Rep. 2022; 7: 280-2. DOI: https://doi.org/10.1093/mrcr/rxac041
  28. Tan CY, Toh TH, Toh YF, Wong KT, Shahrizaila N, Goh KJ. A temporal association between COVID-19 vaccination and immune-mediated necrotizing myopathy. Muscle Nerve. 2022; 65 (6): E24-6. DOI: https://doi.org/10.1002/mus.27531
  29. Dodig D, Fritzler MJ, Naraghi A, Tarnopolsky MA, Lu JQ. Immune-mediated necrotizing myopathy after BNT162b2 vaccination in a patient with antibodies against receptor-binding domain of SARS-CoV-2 and signal recognition particle. Muscle Nerve. 2022; 65: E11-3. DOI: https://doi.org/10.1002/mus.27483
  30. Gouveia J, Barros C, Caldeira M, Ferreira C, Freitas R. Inflammatory myopathy secondary to SARS-CoV-2 vaccination. Isr Med Assoc J. 2022; 24: 444.
  31. Gupta K, Sharma GS, Kumar A. COVID-19 vaccination-associated anti-Jo-1 syndrome. Reumatologia. 2021; 59: 420-2. DOI: https://doi.org/10.5114/reum.2021.111836
  32. Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018; 14: 269-78. DOI: https://doi.org/10.1038/nrrheum.2018.41
  33. Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramirez R, et al. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther. 2013; 15: R48. DOI: https://doi.org/10.1186/ar4207
  34. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from december 2020 to august 2021. JAMA. 2022; 327: 331-40. DOI: https://doi.org/10.1001/jama.2021.24110
  35. Hanson KE, Goddard K, Lewis N, Fireman B, Myers TR, Bakshi N, et al. Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the vaccine safety datalink. JAMA Netw Open. 2022; 5: e228879. DOI: https://doi.org/10.1001/jamanetworkopen.2022.8879
  36. Klomjit N, Alexander MP, Fervenza FC, Zoghby Z, Garg A, Hogan MC, et al. COVID-19 vaccination and glomerulonephritis. Kidney Int Rep. 2021; 6: 2969-78. DOI: https://doi.org/10.1016/j.ekir.2021.09.008
  37. Ding Y, Ge Y. Inflammatory myopathy following coronavirus disease 2019 vaccination: a systematic review. Front Public Health. 2022; 10: 1007637. DOI: https://doi.org/10.3389/fpubh.2022.1007637
  38. Huang YZ, Kuan CC. Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022; 26: 1770-6.

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2023 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.